Notch signaling in prostate cancer: Refining a therapeutic opportunity

Histology and Histopathology

Volumn 31, Issue 2, 2016, Pages 149-157

  Su, Qingtai ^a,b   Xin, Li ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Integrative Molecular and Biomedical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOTCH RECEPTOR;

ANIMAL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; DISEASE COURSE; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMAN; MALE; METABOLISM; MOUSE; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL LINEAGE; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEOSTASIS; HUMANS; MALE; MICE; MICE, TRANSGENIC; PROSTATIC NEOPLASMS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84957543089     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: 10.14670/HH-11-685     Document Type: Review

References (88)

1. Alana L., Sese M., Canovas V., Punyal Y., Fernandez Y., Abasolo I., de Torres I., Ruiz C., Espinosa L., Bigas A., Y Cajal S.R., Fernández P.L., Serras F., Corominas M., Thomson T.M. and Paciucci R. (2014). Prostate tumor overexpressed-1 (PTOV1) down-regulates HES1 and HEY1 notch targets genes and promotes prostate cancer progression. Mol. Cancer 13, 74.
2. Artavanis-Tsakonas S., Rand M.D. and Lake R.J. (1999). Notch signaling: cell fate control and signal integration in development. Science 284, 770-776.
3. Ayyanan A., Civenni G., Ciarloni L., Morel C., Mueller N., Lefort K., Mandinova A., Raffoul W., Fiche M., Dotto G.P. and Brisken C. (2006). Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc. Natl. Acad. Sci. USA 103, 3799-3804.
4. Belandia B., Powell S.M., Garcia-Pedrero J.M., Walker M.M., Bevan C.L. and Parker M.G. (2005). Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Mol. Cell. Biol. 25, 1425-1436.
5. Bertrand F.E., McCubrey J.A., Angus C.W., Nutter J.M. and Sigounas G. (2014). NOTCH and PTEN in prostate cancer. Adv. Biol. Regulat. 56, 51-65.
6. Bin Hafeez B., Adhami V.M., Asim M., Siddiqui I.A., Bhat K.M., Zhong W., Saleem M., Din M., Setaluri V. and Mukhtar H. (2009). Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin. Cancer Res. 15, 452-459.
7. Boutros P.C., Fraser M., Harding N.J., de Borja R., Trudel D., Lalonde E., Meng A., Hennings-Yeomans P.H., McPherson A., Sabelnykova V.Y., Zia A., Fox N.S., Livingstone J., Shiah Y.J., Wang J., Beck T.A., Have C.L., Chong T., Sam M., Johns J., Timms L., Buchner N., Wong A., Watson J.D., Simmons T.T., P'ng C., Zafarana G., Nguyen F., Luo X., Chu K.C., Prokopec S.D., Sykes J., Dal Pra A., Berlin A., Brown A., Chan-Seng-Yue M.A., Yousif F., Denroche R.E., Chong L.C., Chen G.M., Jung E., Fung C., Starmans M.H., Chen H., Govind S.K., Hawley J., D'Costa A., Pintilie M., Waggott D., Hach F., Lambin P., Muthuswamy L.B., Cooper C., Eeles R., Neal D., Tetu B., Sahinalp C., Stein L.D., Fleshner N., Shah S.P., Collins C.C., Hudson T.J., McPherson J.D., van der Kwast T. and Bristow R.G. (2015). Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat. Genet. 47, 736-745.
8. Bray S.J. (2006). Notch signalling: a simple pathway becomes complex. Nat. Rev. Mol. Cell Biol. 7, 678-689.
9. Chiba S. (2006). Notch signaling in stem cell systems. Stem Cells 24, 2437-2447.
10. Cui H., Kong Y., Xu M. and Zhang H. (2013). Notch3 functions as a tumor suppressor by controlling cellular senescence. Cancer Res. 73, 3451-3459.
11. Dail M., Wong J., Lawrence J., O'Connor D., Nakitandwe J., Chen S.C., Xu J., Lee, L.B., Akagi, K., Li, Q., Aster J.C., Pear W.S., Downing J.R., Sampath D. and Shannon K. (2014). Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. Nature 513, 512-516.
12. Dalrymple S., Antony L., Xu Y., Uzgare A.R., Arnold J.T., Savaugeot J., Sokoll L.J., De Marzo A.M. and Isaacs J.T. (2005). Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells. Cancer Res. 65, 9269-9279.
13. Danza G., Di Serio C., Rosati F., Lonetto G., Sturli N., Kacer D., Pennella A., Ventimiglia G., Barucci R., Piscazzi A., Prudovsky I., Landriscina M., Marchionni N. and Tarantini F. (2012). Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells. Mol. Cancer Res. 10, 230-238.
14. del Alamo D., Rouault H. and Schweisguth F. (2011). Mechanism and significance of cis-inhibition in Notch signalling. Curr. Biol. 21, R40-47.
15. Demehri S., Turkoz A. and Kopan R. (2009). Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer cell 16, 55-66.
16. Domingo-Domenech J., Vidal S.J., Rodriguez-Bravo V., Castillo-Martin M., Quinn S.A., Rodriguez-Barrueco R., Bonal, D.M., Charytonowicz, E., Gladoun, N., de la Iglesia-Vicente, J., Petrylak D.P., Benson M.C., Silva J.M. and Cordon-Cardo C. (2012). Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumorinitiating cells. Cancer Cell 22, 373-388.
17. Ellisen L.W., Bird J., West D.C., Soreng A.L., Reynolds T.C., Smith S.D. and Sklar J. (1991). TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66, 649-661.
18. Ellwood-Yen K., Graeber T.G., Wongvipat J., Iruela-Arispe M.L., Zhang J., Matusik R., Thomas G.V. and Sawyers, C.L. (2003). Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4, 223-238.
19. Fitzgerald K., Harrington A. and Leder P. (2000). Ras pathway signals are required for notch-mediated oncogenesis. Oncogene 19, 4191-4198.
20. Gallahan D. and Callahan R. (1987). Mammary tumorigenesis in feral mice: identification of a new int locus in mouse mammary tumor virus (Czech II)-induced mammary tumors. J. Virol. 61, 66-74.
21. Gao D., Vela I., Sboner A., Iaquinta P.J., Karthaus W.R., Gopalan A., Dowling C., Wanjala J.N., Undvall E.A., Arora V.K., Wongvipat J., Kossai M., Ramazanoglu S., Barboza L.P., Di W., Cao Z., Zhang Q.F., Sirota I., Ran L., MacDonald T.Y., Beltran H., Mosquera J.M., Touijer K.A., Scardino P.T., Laudone V.P., Curtis K.R., Rathkopf D.E., Morris M.J., Danila D.C., Slovin S.F., Solomon S.B., Eastham J.A., Chi P., Carver B., Rubin M.A., Scher H.I., Clevers H., Sawyers C.L. and Chen Y. (2014). Organoid cultures derived from patients with advanced prostate cancer. Cell 159, 176-187.
22. Gipp J., Gu G., Crylen C., Kasper S. and Bushman W. (2007). Hedgehog pathway activity in the LADY prostate tumor model. Mol. Cancer 6, 19.
23. Greenberg N.M., DeMayo F., Finegold M.J., Medina D., Tilley W.D., Aspinall J.O., Cunha G.R., Donjacour A.A., Matusik R.J. and Rosen J.M. (1995). Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA 92, 3439-3443.
24. Hahm E.R., Chandra-Kuntal K., Desai D., Amin S. and Singh S.V. (2012). Notch activation is dispensable for D, L-sulforaphanemediated inhibition of human prostate cancer cell migration. PloS One 7, e44957.
25. Han J., Hendzel M.J. and Allalunis-Turner J. (2011). Notch signaling as a therapeutic target for breast cancer treatment? Breast CancerRes. 13, 210.
26. Harrison H., Farnie G., Howell S.J., Rock R.E., Stylianou S., Brennan K.R., Bundred N.J. and Clarke R.B. (2010). Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 70, 709-718.
27. Hu C., Dievart A., Lupien M., Calvo E., Tremblay G. and Jolicoeur P. (2006). Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors. Am. J. Pathol. 168, 973-990.
28. Hu Y., Ippolito J.E., Garabedian E.M., Humphrey P.A. and Gordon J.I. (2002). Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice. J. Biol. Chem. 277, 44462-44474.
29. Hudson R.S., Yi M., Esposito D., Watkins S.K., Hurwitz A.A., Yfantis H.G., Lee D.H., Borin J.F., Naslund M.J., Alexander R.B., Dorsey T.H., Stephens R.M., Croce C.M. and Ambs S. (2012). MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res. 40, 3689-3703.
30. Jhappan C. Gallahan, D., Stahle, C., Chu, E., Smith, G.H., Merlino, G. and Callahan, R. (1992). Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. Genes Dev. 6, 345-355.
31. Kandachar V. and Roegiers F. (2012). Endocytosis and control of Notch signaling. Curr. Opin. Cell Biol. 24, 534-540.
32. Kangsamaksin T., Murtomaki A., Kofler N.M., Cuervo H., Chaudhri R.A., Tattersall I.W., Rosenstiel P.E., Shawber C.J. and Kitajewski J. (2015). NOTCH decoys that selectively block DLL/NOTCH or JAG/NOTCH disrupt angiogenesis by unique mechanisms to inhibit tumor growth. Cancer Discovery 5, 182-197.
33. Karthaus W.R., Iaquinta P.J., Drost J., Gracanin A., van Boxtel R., Wongvipat J., Dowling C.M., Gao D., Begthel H., Sachs N., Vries R.G., Cuppen E., Chen Y., Sawyers C.L. and Clevers H.C. (2014). Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell 159, 163-175.
34. Kashat M., Azzouz L., Sarkar S.H., Kong D., Li, Y. and Sarkar F.H. (2012). Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness. Am. J. Translat. Res. 4, 432-442.
35. Klinakis A., Lobry C., Abdel-Wahab O., Oh P., Haeno H., Buonamici S., van De Walle I., Cathelin S., Trimarchi T., Araldi E., Liu C., Ibrahim S., Beran M., Zavadil J., Efstratiadis A., Taghon T., Michor F., Levine R.L. and Aifantis I. (2011). A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 473, 230-233.
36. Kopan R. and Ilagan M.X. (2009). The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137, 216-233.
37. Kwon O.J., Valdez J.M., Zhang L., Zhang B., Wei X., Su Q., Ittmann M.M., Creighton C.J. and Xin L. (2014). Increased Notch signalling inhibits anoikis and stimulates proliferation of prostate luminal epithelial cells. Nat. Communicat. 5, 4416.
38. LaTulippe E., Satagopan J., Smith A., Scher H., Scardino, P., Reuter, V. and Gerald, W.L. (2002). Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 62, 4499-4506.
39. Lavery D.N., Villaronga M.A., Walker M.M., Patel A., Belandia B. and Bevan C.L. (2011). Repression of androgen receptor activity by HEYL, a third member of the Hairy/Enhancer-of-split-related family of Notch effectors. J. Biol. Chem. 286, 17796-17808.
40. Leong K.G. and Gao W.Q. (2008). The Notch pathway in prostate development and cancer. Differentiation 76, 699-716.
41. Li J.L., Sainson R.C., Shi W., Leek R., Harrington L.S., Preusser M., Biswas S., Turley H., Heikamp E., Hainfellner J.A. and Harris A.L. (2007). Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res. 67, 11244-11253.
42. Litvinov I.V., Antony L., Dalrymple S.L., Becker R., Cheng L. and Isaacs J.T. (2006). PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate 66, 1329-1338.
43. Maliekal T.T., Bajaj J., Giri, V., Subramanyam D. and Krishna, S. (2008). The role of Notch signaling in human cervical cancer: implications for solid tumors. Oncogene 27, 5110-5114.
44. Maraver A., Fernandez-Marcos P.J., Cash T.P., Mendez-Pertuz M., Duenas M., Maietta P., Martinelli P., Munoz-Martin M., Martinez- Fernandez M., Canamero M., Roncador G., Martinez-Torrecuadrada J.L., Grivas D., de la Pompa J.L., Valencia A., Paramio J.M., Real F.X. and Serrano M. (2015). NOTCH pathway inactivation promotes bladder cancer progression. J. Clin. Invest. 125, 824-830.
45. Masumori N., Thomas T.Z., Chaurand P., Case T., Paul M., Kasper S., Caprioli R.M., Tsukamoto T., Shappell S.B. and Matusik R.J. (2001). A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res. 61, 2239-2249.
46. Mazzone M., Selfors L.M., Albeck J., Overholtzer M., Sale S., Carroll D.L., Pandya D., Lu Y., Mills G.B., Aster J.C., Artavanis-Tsakonas S. and Brugge J.S. (2010). Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc. Natl. Acad. Sci. USA 107, 5012-5017.
47. Mumm J.S. and Kopan R. (2000). Notch signaling: from the outside in. Dev. Biol. 228, 151-165.
48. Musse A.A., Meloty-Kapella L. and Weinmaster G. (2012). Notch ligand endocytosis: mechanistic basis of signaling activity. Semin. Cell Dev. Biol. 23, 429-436.
49. Ntziachristos P., Lim J.S., Sage J. and Aifantis I. (2014). From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell 25, 318-334.
50. Orr B., Grace O.C., Vanpoucke G., Ashley G.R. and Thomson A.A. (2009). A role for notch signaling in stromal survival and differentiation during prostate development. Endocrinology 150, 463-472.
51. Parr C., Watkins G. and Jiang W.G. (2004). The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int. J. Mol. Med. 14, 779-786.
52. Pear W.S., Aster J.C., Scott M.L., Hasserjian R.P., Soffer B., Sklar J. and Baltimore D. (1996). Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J. Exp. Med. 183, 2283-2291.
53. Qiao L. and Wong B.C. (2009). Role of Notch signaling in colorectal cancer. Carcinogenesis 30, 1979-1986.
54. Ranganathan P., Weaver K.L. and Capobianco A.J. (2011). Notch signalling in solid tumours: a little bit of everything but not all the time. Nat. Rev. Cancer 11, 338-351.
55. Robinson D.R., Kalyana-Sundaram S., Wu Y.M., Shankar S., Cao X., Ateeq B., Asangani I.A., Iyer M., Maher C.A., Grasso C.S., Lonigro R.J., Quist M., Siddiqui J., Mehra R., Jing X., Giordano T.J., Sabel M.S., Kleer C.G., Palanisamy N., Natrajan R., Lambros M.B., Reis- Filho J.S., Kumar-Sinha C. and Chinnaiyan A.M. (2011). Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nature Med. 17, 1646-1651.
56. Rose S.L., Kunnimalaiyaan M., Drenzek J. and Seiler N. (2010). Notch 1 signaling is active in ovarian cancer. Gynecol. Oncol. 117, 130-133.
57. Ross A.E., Marchionni L., Vuica-Ross M., Cheadle C., Fan J., Berman D.M. and Schaeffer E.M. (2011). Gene expression pathways of high grade localized prostate cancer. Prostate 71,1568-1577.
58. Santagata S., Demichelis F., Riva, A., Varambally S., Hofer M.D., Kutok J.L., Kim R., Tang J., Montie J.E., Chinnaiyan A.M., Rubin M.A. and Aster J.C. (2004). JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res. 64, 6854-6857.
59. Scorey N., Fraser S.P., Patel P., Pridgeon C., Dallman M.J. and Djamgoz M.B. (2006). Notch signalling and voltage-gated Na+ channel activity in human prostate cancer cells: independent modulation of in vitro motility. Prostate Cancer Prostatic Dis. 9, 399-406.
60. Sethi S., Macoska J., Chen W. and Sarkar F.H. (2010). Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am. J. Translat. Res. 3, 90-99.
61. Sethi N., Dai X., Winter C.G. and Kang Y. (2011). Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 19, 192-205.
62. Shahi P., Seethammagari M.R., Valdez J.M., Xin L. and Spencer, D.M. (2011). Wnt and Notch pathways have interrelated opposing roles on prostate progenitor cell proliferation and differentiation. Stem Cells 29, 678-688.
63. Sharma A., Gadkari R.A., Ramakanth S.V., Padmanabhan K., Madhumathi D.S., Devi L., Appaji L., Aster J.C., Rangarajan A. and Dighe R.R. (2015). A novel monoclonal antibody against notch1 targets leukemia-associated mutant notch1 and depletes therapy resistant cancer stem cells in solid tumors. Scientif. Rep. 5, 11012.
64. Shou J., Ross S., Koeppen H., de Sauvage F.J. and Gao W.Q. (2001). Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Res. 61, 7291-7297.
65. Takeuchi H. and Haltiwanger R.S. (2014). Significance of glycosylation in Notch signaling. Biochem. Biophys. Res. Commun. 453, 235-242.
66. Valdez J.M., Zhang L., Su Q., Dakhova O., Zhang Y., Shahi, P., Spencer, D.M., Creighton, C.J., Ittmann, M.M. and Xin, L. (2012). Notch and TGFbeta form a reciprocal positive regulatory loop that suppresses murine prostate basal stem/progenitor cell activity. Cell Stem Cell 11, 676-688.
67. Villaronga M.A., Bevan C.L. and Belandia B. (2008). Notch signaling: a potential therapeutic target in prostate cancer. Curr. Cancer Drug Targets 8, 566-580.
68. Wang S., Gao J., Lei Q., Rozengurt N., Pritchard C., Jiao J., Thomas G.V., Li G., Roy-Burman P., Nelson P.S., Liu X. and Wu H. (2003). Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209-221.
69. Wang X.D., Leow C.C., Zha J., Tang Z., Modrusan Z. Radtke, F., Aguet, M., de Sauvage, F.J. and Gao, W.Q. (2006). Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. Dev. Biol. 290, 66-80.
70. Wang Z., Li Y., Banerjee S., Kong D., Ahmad A., Nogueira V., Hay N. and Sarkar F.H. (2010). Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J. Cell. Biochem. 109, 726-736.
71. Wang H., Zou J., Zhao B., Johannsen E., Ashworth T., Wong H., Pear W.S., Schug J., Blacklow S.C., Arnett K.L., Bernstein B.E., Kieff E. and Aster J.C. (2011a). Genome-wide analysis reveals conserved and divergent features of Notch1/RBPJ binding in human and murine T-lymphoblastic leukemia cells. Proc. Natl. Acad. Sci. USA 108, 14908-14913.
72. Wang N.J., Sanborn Z., Arnett K.L., Bayston L.J., Liao W., Proby C.M., Leigh I.M., Collisson E.A., Gordon P.B., Jakkula L., Pennypacker S., Zou Y., Sharma M., North J.P., Vemula S.S., Mauro T.M., Neuhaus I.M., Leboit P.E., Hur J.S., Park K., Huh N., Kwok P.Y., Arron S.T., Massion P.P., Bale A.E., Haussler D., Cleaver J.E., Gray J.W., Spellman P.T., South A.P., Aster J.C., Blacklow S.C. and Cho R.J. (2011b). Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc. Natl. Acad. Sci. USA 108, 17761-17766.
73. Wang, Z., Li Y., Ahmad A., Banerjee S., Azmi A.S., Kong D., Wojewoda C., Miele L. and Sarkar F.H. (2011c). Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. J. Cell. Biochem. 112, 78-88.
74. Wang K., Zhang Q., Li D., Ching K., Zhang C., Zheng X., Ozeck M., Shi S., Li X., Wang H., Rejto P., Christensen J. and Olson P. (2015). PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a gamma-secretase inhibitor. Clinical cancer research: an official journal of the American Association for Cancer Research 21, 1487-1496.
75. Weng A.P., Ferrando A.A., Lee W., Morris J.P.t., Silverman L.B., Sanchez-Irizarry C., Blacklow S.C., Look A.T. and Aster J.C. (2004). Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269-271.
76. Whelan J.T., Forbes S.L. and Bertrand F.E. (2007). CBF-1 (RBP-J kappa) binds to the PTEN promoter and regulates PTEN gene expression. Cell Cycle 6, 80-84.
77. Whelan J.T., Kellogg A., Shewchuk B.M., Hewan-Lowe K. and Bertrand F.E. (2009). Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression. J. Cell. Biochem. 107, 992-1001.
78. Wu X., Xu K., Zhang L., Deng Y., Lee P., Shapiro E., Monaco M., Makarenkova H.P., Li J., Lepor H. and Grishina I. (2011). Differentiation of the ductal epithelium and smooth muscle in the prostate gland are regulated by the Notch/PTEN-dependent mechanism. Dev. Biol. 356, 337-349.
79. Xin L., Ide H., Kim Y., Dubey P. and Witte, O.N. (2003). In vivo regeneration of murine prostate from dissociated cell populations of postnatal epithelia and urogenital sinus mesenchyme. Proc. Natl. Acad. Sci. USA 100 (Suppl 1), 11896-11903.
80. Xin L., Lukacs R.U., Lawson D.A., Cheng D. and Witte O.N. (2007). Self-renewal and multilineage differentiation in vitro from murine prostate stem cells. Stem Cells 25, 2760-2769.
81. Ye Q.F., Zhan Y.C., Peng X.Q., Long Z., Ming Y.Z. and He L.Y. (2012). Silencing Notch-1 induces apoptosis and increases the chemosensitivity of prostate cancer cells to docetaxel through Bcl-2 and Bax. Oncol. Lett. 3, 879-884.
82. Yong T., Sun A., Henry M.D., Meyers S. and Davis J.N. (2011). Down regulation of CSL activity inhibits cell proliferation in prostate and breast cancer cells. J. Cell. Biochem. 112, 2340-2351.
83. Yu Y., Zhang Y., Guan W., Huang T., Kang J., Sheng X. and Qi, J. (2014). Androgen receptor promotes the oncogenic function of overexpressed Jagged1 in prostate cancer by enhancing cyclin B1 expression via Akt phosphorylation. Mol. Cancer Res. 12, 830-842.
84. Zardawi S.J., Zardawi I., McNeil C.M., Millar E.K., McLeod D., Morey A.L., Crea P., Murphy N.C., Pinese M., Lopez-Knowles E., Oakes S.R., Ormandy C.J., Qiu M.R., Hamilton A., Spillane A., Soon Lee C., Sutherland R.L., Musgrove E.A. and O'Toole S.A. (2010). High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype. Histopathology 56, 286-296.
85. Zayzafoon M., Abdulkadir S.A. and McDonald J.M. (2004). Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J. Biol. Chem. 279, 3662-3670.
86. Zhang S., Chung W.C., Wu G., Egan S.E. and Xu K. (2014). Tumorsuppressive activity of Lunatic Fringe in prostate through differential modulation of Notch receptor activation. Neoplasia 16, 158-167.
87. Zhang Y., Wang Z., Ahmed F., Banerjee S., Li Y. and Sarkar F.H. (2006). Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells. Int. J. Cancer 119, 2071-2077.
88. Zhu H., Zhou X., Redfie ld S., Lewin J. and Miele L. (2013). Elevated Jagged-1 and Notch-1 expression in high grade and metastatic prostate cancers. Am. J. Transl. Res. 5, 368-378.